Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions
- PMID: 21159728
- PMCID: PMC3770457
- DOI: 10.1176/appi.ajp.2010.10020165
Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions
Abstract
Objective: Schizotypal personality traits are associated with schizophrenia spectrum disorders, and individuals with schizophrenia spectrum disorders demonstrate increased dopamine transmission in the striatum. The authors sought to determine whether individual differences in normal variation in schizotypal traits are correlated with dopamine transmission in the striatum and in extrastriatal brain regions.
Method: Sixty-three healthy volunteers with no history of psychiatric illness completed the Schizotypal Personality Questionnaire and underwent positron emission tomography imaging with [(18)F]fallypride at baseline and after administration of oral d-amphetamine (0.43 mg/kg). Dopamine release, quantified by subtracting each participant's d-amphetamine scan from his or her baseline scan, was correlated with Schizotypal Personality Questionnaire total and factor scores using region-of-interest and voxel-wise analyses.
Results: Dopamine release in the striatum was positively correlated with overall schizotypal traits. The association was especially robust in the associative subdivision of the striatum. Voxel-wise analyses identified additional correlations between dopamine release and schizotypal traits in the left middle frontal gyrus and left supramarginal gyrus. Exploratory analyses of Schizotypal Personality Questionnaire factor scores revealed correlations between dopamine release and disorganized schizotypal traits in the striatum, thalamus, medial prefrontal cortex, temporal lobe, insula, and inferior frontal cortex.
Conclusions: The association between dopamine signaling and psychosis phenotypes extends to individual differences in normal variation in schizotypal traits and involves dopamine transmission in both striatal and extrastriatal brain regions. Amphetamine-induced dopamine release may be a useful endophenotype for investigating the genetic basis of schizophrenia spectrum disorders.
Conflict of interest statement
Conflict of interest statement: Dr. Robert M. Kessler holds a patent for the use of Fallypride in humans, although there are no plans currently to use it commercially. None of the remaining authors report any conflicts of interest.
Figures
References
-
- Widiger TA, Mullins-Sweatt SN. Five-factor model of personality disorder: a proposal for DSM-V. Annu.Rev.Clin.Psychol. 2009;5:197–220. - PubMed
-
- Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophrenia Bulletin. 1991;17(4):555–564. - PubMed
-
- Compton MT, Goulding SM, Bakeman R, Clure-Tone EB. Confirmation of a four-factor structure of the Schizotypal Personality Questionnaire among undergraduate students. Schizophrenia Research. 2009;111(1–3):46–52. - PubMed
-
- Gruzelier JH. The factorial structure of schizotypy: Part I. Affinities with syndromes of schizophrenia. Schizophrenia Bulletin. 1996;22(4):611–620. - PubMed
-
- Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophrenia Bulletin. 2009;35(5):894–908. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
